Steve Schonfeld’s Arcutis Biotherapeutics ARQT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$537K Buy
+20,303
New +$531K ﹤0.01% 1936
2025
Q4
– Sell
-189,555
Closed -$3.57M – 2040
2025
Q3
$3.57M Sell
189,555
-330,729
-64% -$5.22M 0.02% 748
2025
Q2
$7.29M Buy
520,284
+501,818
+2,718% +$7.03M 0.05% 439
2025
Q1
$289K Sell
18,466
-4,534
-20% -$63.9K ﹤0.01% 1808
2024
Q4
$320K Sell
23,000
-7,349
-24% -$80.5K ﹤0.01% 1589
2024
Q3
$282K Buy
30,349
+14,175
+88% +$140K ﹤0.01% 1679
2024
Q2
$150K Buy
+16,174
New +$146K ﹤0.01% 1848
2023
Q1
– Sell
-28,100
Closed -$416K – 2085
2022
Q4
$416K Buy
+28,100
New +$491K ﹤0.01% 1627
2022
Q2
– Sell
-17,996
Closed -$347K – 2514
2022
Q1
$347K Buy
+17,996
New +$304K ﹤0.01% 1596

Other funds holding ARQT

Steve Schonfeld's ARQT Position: Q3 2026 in Review

Steve Schonfeld opened a new position in Arcutis Biotherapeutics (ARQT) in Q3 2026: 20,303 shares worth $537K. The stake represents ﹤0.01% of the portfolio and ranks #1936 among its holdings. This is a return to the name: Steve Schonfeld previously reported a position in ARQT as recently as Q3 2025.

Steve Schonfeld first reported a position in ARQT in Q1 2022 and has held it in 9 quarters since. The position peaked at $7.29M in Q2 2025. 294 funds tracked by Wall St. Rank hold ARQT as of Q3 2026.

  • Steve Schonfeld held 20,303 shares of Arcutis Biotherapeutics worth $537K as of Q3 2026.
  • Arcutis Biotherapeutics was a new Steve Schonfeld position in Q3 2026.
  • Arcutis Biotherapeutics made up ﹤0.01% of Steve Schonfeld's portfolio in Q3 2026, its #1936 holding.
  • Steve Schonfeld first reported a position in Arcutis Biotherapeutics in Q1 2022 and has held it in 9 quarters since.
  • Steve Schonfeld's Arcutis Biotherapeutics position peaked at $7.29M in Q2 2025.
  • 294 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.